| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC3528 |
| Trial ID | NCT05972720 |
| Disease | Large B-Cell Lymphoma |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | firi-cel|Firicabtagene autoleucel |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Firi-cel, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell Therapy |
| Year | 2023 |
| Country | United States |
| Company sponsor | CARGO Therapeutics |
| Other ID(s) | CRG-022-101 |
| Cohort 1 | |||||||||||
|
|||||||||||